Physician profile
Michael Jiser
NPI 1952386005
$74,196.51
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,633 · 2020: $120 · 2021: $1,724 · 2022: $29K · 2023: $15K · 2024: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $32K · Food and Beverage: $3,993 · Consulting Fee: $2,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $32,000.00 |
| Food and Beverage | $3,993.25 |
| Consulting Fee | $2,320.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $60,866.20 | 2021-2024 | Da Vinci Surgical System |
| Medtronic, INC. | $5,067.10 | 2021-2024 | Signia, Ligasure, Parietene Ds |
| Covidien Lp | $4,611.02 | 2019-2020 | |
| Tela Bio, INC. | $1,904.83 | 2022-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| W. L. Gore & Associates, INC. | $1,154.89 | 2019-2024 | Gore Synecor Biomaterial, Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Stryker Corporation | $205.94 | 2021 | |
| Teleflex LLC | $171.46 | 2021-2024 | Titan Sgs |
| Nuvasive, INC. | $96.95 | 2023 | Pulse |
| Davol INC. | $45.00 | 2023 | Phasix Mesh |
| Pacira Pharmaceuticals Incorporated | $30.56 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $27.24 | 2019 | |
| Baudax Bio INC. | $15.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.